Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
Trust and our long-term performance
Emma Walmsley, CEO, will speak at CECP’s CEO Investor Forum on 20 September 2018 at 10:30am EDT. She will talk about the steps we are taking to build trust – one of our three long-term priorities – and drive sustainable business performance.
Latest information
Latest press releases
- GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
- GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
- Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
Second quarter 2018 results and R&D update
We announced our second quarter 2018 results for the period ended 30 June 2018 and R&D update on Wednesday 25 July.